misses expectations Eli Lilly 2012 profit forecast misses expectationsEli Lilly 2012 profit forecast misses expectationsTOM MURPHY
The article reports on the increase in the fourth-quarter profit of Eli Lilly & Co. due to increased sales of drugs for mental illness and cancer. Unlike other pharmaceutical companies which face problems, the company's problem is expected to heat up in 2011 when its bestselling antipsychotic...
constitutes the largest market for global hospital pharmaceuticals market in 2013; however, Asia-Pacific is predicted to foresee the highest growth rate during the forecast period from 2014 to 2020. This growth has been attributed to large population base and increasing incidences of cardiovascular dis...
Feb 6 (Reuters) - Eli Lilly and Co cut its 2019 forecast for profit and revenue on Wednesday, citing the recent trial failure of its conditionally approved cancer drug Lartruvo and costs related to its pending acquisition of Loxo Oncology. Indianapolis-based Lilly is betting on new drugs and...
View that Strattera is a promising new, non-stimulant, first-line option for the treatment of ADHD; Forecast of$1.4 billion in Strattera worldwide sales in the year 2007; Predictions as to the market share that would be overtaken by Strattera; Description of side effects that can be caused ...